[Clinical application of gene technology for diagnosis and treatment of leukemia].
Recently, clinical application of gene technology in oncology and hematology has been markedly advanced. Pathogenesis of leukemic transformation has been thought that it was resulted from cumulation of activation or mutation in oncogenes or onco-suppressor genes. As a matter of fact, many specific chromosomal abnormalities in leukemias have been thought to be due to production of chimeric fusion gene by translocation and activation in some kinds of oncogenes under specific regulatory genes after translocation. In addition to those, inactivation of onco-suppressor genes, such as RB gene or p53 gene, may be also related to leukemogenesis in some leukemias. Laboratory examinations using molecular technology are being necessary for clinical diagnosis and treatment in many hematological disorders. The examinations detecting rearrangement of major BCR or minor BCR in Ph1 positive leukemias, TCR in T cell malignancy, immunoglobulin in B cell malignancy, PML-RAR alpha fusion gene in APL have become routine for diagnosis of some leukemias. Moreover, these examinations are useful for judgement of treatment effects and evaluation of minimal residual diseases. In this paper, we also discuss the usefulness and importance of these technology especially in stem cell transplantation and cytokine therapy, and the future possibility in this technology for gene therapy.
Hashino
S
S
3rd Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo.
Imamura
M
M
D016207:Cytokines / Q000627:therapeutic use; D005818:Genetic Engineering; D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D014212:Tretinoin / Q000627:therapeutic use
D016207:Cytokines; D012333:RNA, Messenger; D014212:Tretinoin